{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:13:50Z","timestamp":1791231230744,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"japan society for the promotion of science","doi-asserted-by":"publisher","award":["JP15K21114"],"award-info":[{"award-number":["JP15K21114"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"japan agency for medical research and development","doi-asserted-by":"publisher","award":["JP16bm0704008"],"award-info":[{"award-number":["JP16bm0704008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"kyorin pharmaceutical co.ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Somatic cells differentiated from patient-specific human induced pluripotent stem cells (iPSCs) could be a useful tool in human cell-based disease research. Hermansky\u2013Pudlak syndrome (HPS) is an autosomal recessive genetic disorder characterized by oculocutaneous albinism and a platelet dysfunction. HPS patients often suffer from lethal HPS associated interstitial pneumonia (HPSIP). Lung transplantation has been the only treatment for HPSIP. Lysosome-related organelles are impaired in HPS, thereby disrupting alveolar type 2 (AT2) cells with lamellar bodies. HPSIP lungs are characterized by enlarged lamellar bodies. Despite species differences between human and mouse in HPSIP, most studies have been conducted in mice since culturing human AT2 cells is difficult.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We generated patient-specific iPSCs from patient-derived fibroblasts with the most common bi-allelic variant, c.1472_1487dup16, in HPS1 for modeling severe phenotypes of HPSIP. We then corrected the variant of patient-specific iPSCs using CRISPR-based microhomology-mediated end joining to obtain isogenic controls. The iPSCs were then differentiated into lung epithelial cells using two different lung organoid models, lung bud organoids (LBOs) and alveolar organoids (AOs), and explored the phenotypes contributing to the pathogenesis of HPSIP using transcriptomic and proteomic analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The LBOs derived from patient-specific iPSCs successfully recapitulated the abnormalities in morphology and size. Proteomic analysis of AOs involving iPSC-derived AT2 cells and primary lung fibroblasts revealed mitochondrial dysfunction in <jats:italic>HPS1<\/jats:italic> patient-specific alveolar epithelial cells. Further, giant lamellar bodies were recapitulated in patient-specific AT2 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The HPS1 patient-specific iPSCs and their gene-corrected counterparts generated in this study could be a new research tool for understanding the pathogenesis of HPSIP caused by <jats:italic>HPS1<\/jats:italic> deficiency in humans.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-021-01877-8","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T13:02:23Z","timestamp":1636030943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Modeling of lung phenotype of Hermansky\u2013Pudlak syndrome type I using patient-specific iPSCs"],"prefix":"10.1186","volume":"22","author":[{"given":"Takahiro","family":"Suezawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kanagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Korogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyohiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8563-8200","authenticated-orcid":false,"given":"Shimpei","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"1877_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12015-019-09935-x","volume":"16","author":"G Liu","year":"2020","unstructured":"Liu G, David BT, Trawczynski M, Fessler RG. Advances in pluripotent stem cells: history, mechanisms, technologies, and applications. Stem Cell Rev Rep. 2020;16:3\u201332.","journal-title":"Stem Cell Rev Rep"},{"key":"1877_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd.2016.245","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:115\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"1877_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.stemcr.2019.01.014","volume":"12","author":"Y Korogi","year":"2019","unstructured":"Korogi Y, Gotoh S, Ikeo S, Yamamoto Y, Sone N, Tamai K, Konishi S, Nagasaki T, Matsumoto H, Ito I, et al. In vitro disease modeling of Hermansky\u2013Pudlak syndrome type 2 using human induced pluripotent stem cell-derived alveolar organoids. Stem Cell Rep. 2019;12:431\u201340.","journal-title":"Stem Cell Rep"},{"key":"1877_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1124\/pr.116.013003","volume":"72","author":"DT Paik","year":"2020","unstructured":"Paik DT, Chandy M, Wu JC. Patient and disease-specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics. Pharmacol Rev. 2020;72:320\u201342.","journal-title":"Pharmacol Rev"},{"key":"1877_CR5","unstructured":"Huizing M, Malicdan MCV, Gochuico BR, Gahl WA. Hermansky\u2013Pudlak Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews. University of Washington, Seattle. 2000 (updated 2021 Mar 18)."},{"key":"1877_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/tra.12646","volume":"20","author":"SL Bowman","year":"2019","unstructured":"Bowman SL, Bi-Karchin J, Le L, Marks MS. The road to lysosome-related organelles: insights from Hermansky\u2013Pudlak syndrome and other rare diseases. Traffic. 2019;20:404\u201335.","journal-title":"Traffic"},{"key":"1877_CR7","first-page":"1839","volume":"13","author":"GW Vicary","year":"2016","unstructured":"Vicary GW, Vergne Y, Santiago-Cornier A, Young LR, Roman J. Pulmonary fibrosis in Hermansky\u2013Pudlak syndrome. Ann Am Thorac Soc. 2016;13:1839\u201346.","journal-title":"Ann Am Thorac Soc"},{"key":"1877_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.644671","volume":"12","author":"P Vel\u00e1zquez-D\u00edaz","year":"2021","unstructured":"Vel\u00e1zquez-D\u00edaz P, Nakajima E, Sorkhdini P, Hernandez-Gutierrez A, Eberle A, Yang D, Zhou Y. Hermansky-Pudlak syndrome and lung disease: pathogenesis and therapeutics. Front Pharmacol. 2021;12: 644671.","journal-title":"Front Pharmacol"},{"key":"1877_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.jid.5700034","volume":"126","author":"PJ Santiago Borrero","year":"2006","unstructured":"Santiago Borrero PJ, Rodr\u00edguez-P\u00e9rez Y, Renta JY, Izquierdo NJ, Del Fierro L, Mu\u00f1oz D, Molina NL, Ram\u00edrez S, Pag\u00e1n-Mercado G, Ort\u00edz I, et al. Genetic testing for oculocutaneous albinism type 1 and 2 and Hermansky\u2013Pudlak syndrome type 1 and 3 mutations in Puerto Rico. J Invest Dermatol. 2006;126:85\u201390.","journal-title":"J Invest Dermatol"},{"key":"1877_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0193-2020","author":"T Yokoyama","year":"2021","unstructured":"Yokoyama T, Gochuico BR. Hermansky\u2013Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease. Eur Respir Rev. 2021. https:\/\/doi.org\/10.1183\/16000617.0193-2020.","journal-title":"Eur Respir Rev"},{"key":"1877_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s004280000241","volume":"437","author":"Y Nakatani","year":"2000","unstructured":"Nakatani Y, Nakamura N, Sano J, Inayama Y, Kawano N, Yamanaka S, Miyagi Y, Nagashima Y, Ohbayashi C, Mizushima M, et al. Interstitial pneumonia in Hermansky\u2013Pudlak syndrome: significance of florid foamy swelling\/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch. 2000;437:304\u201313.","journal-title":"Virchows Arch"},{"key":"1877_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1164\/rccm.200901-0023OC","volume":"180","author":"FN Rouhani","year":"2009","unstructured":"Rouhani FN, Brantly ML, Markello TC, Helip-Wooley A, O\u2019Brien K, Hess R, Huizing M, Gahl WA, Gochuico BR. Alveolar macrophage dysregulation in Hermansky\u2013Pudlak syndrome type 1. Am J Respir Crit Care Med. 2009;180:1114\u201321.","journal-title":"Am J Respir Crit Care Med"},{"key":"1877_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1165\/rcmb.2013-0025OC","volume":"50","author":"AR Cullinane","year":"2014","unstructured":"Cullinane AR, Yeager C, Dorward H, Carmona-Rivera C, Wu HP, Moss J, O\u2019Brien KJ, Nathan SD, Meyer KC, Rosas IO, et al. Dysregulation of galectin-3. Implications for Hermansky\u2013Pudlak syndrome pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014;50:605\u201313.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1877_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159177","volume":"11","author":"AS Kirshenbaum","year":"2016","unstructured":"Kirshenbaum AS, Cruse G, Desai A, Bandara G, Leerkes M, Lee CC, Fischer ER, O\u2019Brien KJ, Gochuico BR, Stone K, et al. Immunophenotypic and ultrastructural analysis of mast cells in Hermansky\u2013Pudlak syndrome type-1: a possible connection to pulmonary fibrosis. PLoS ONE. 2016;11: e0159177.","journal-title":"PLoS ONE"},{"key":"1877_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1164\/rccm.200909-1414OC","volume":"182","author":"P Mahavadi","year":"2010","unstructured":"Mahavadi P, Korfei M, Henneke I, Liebisch G, Schmitz G, Gochuico BR, Markart P, Bellusci S, Seeger W, Ruppert C, Guenther A. Epithelial stress and apoptosis underlie Hermansky\u2013Pudlak syndrome-associated interstitial pneumonia. Am J Respir Crit Care Med. 2010;182:207\u201319.","journal-title":"Am J Respir Crit Care Med"},{"key":"1877_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1164\/rccm.201207-1206OC","volume":"186","author":"LR Young","year":"2012","unstructured":"Young LR, Gulleman PM, Bridges JP, Weaver TE, Deutsch GH, Blackwell TS, McCormack FX. The alveolar epithelium determines susceptibility to lung fibrosis in Hermansky\u2013Pudlak syndrome. Am J Respir Crit Care Med. 2012;186:1014\u201324.","journal-title":"Am J Respir Crit Care Med"},{"key":"1877_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/ncb3510","volume":"19","author":"YW Chen","year":"2017","unstructured":"Chen YW, Huang SX, de Carvalho A, Ho SH, Islam MN, Volpi S, Notarangelo LD, Ciancanelli M, Casanova JL, Bhattacharya J, et al. A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol. 2017;19:542\u20139.","journal-title":"Nat Cell Biol"},{"key":"1877_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.stemcr.2014.07.005","volume":"3","author":"S Gotoh","year":"2014","unstructured":"Gotoh S, Ito I, Nagasaki T, Yamamoto Y, Konishi S, Korogi Y, Matsumoto H, Muro S, Hirai T, Funato M, et al. Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells. Stem Cell Rep. 2014;3:394\u2013403.","journal-title":"Stem Cell Rep"},{"key":"1877_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.stemcr.2015.11.010","volume":"6","author":"S Konishi","year":"2016","unstructured":"Konishi S, Gotoh S, Tateishi K, Yamamoto Y, Korogi Y, Nagasaki T, Matsumoto H, Muro S, Hirai T, Ito I, et al. directed induction of functional multi-ciliated cells in proximal airway epithelial spheroids from human pluripotent stem cells. Stem Cell Rep. 2016;6:18\u201325.","journal-title":"Stem Cell Rep"},{"key":"1877_CR20","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/nmeth.4448","volume":"14","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto Y, Gotoh S, Korogi Y, Seki M, Konishi S, Ikeo S, Sone N, Nagasaki T, Matsumoto H, Muro S, et al. Long-term expansion of alveolar stem cells derived from human iPS cells in organoids. Nat Methods. 2017;14:1097\u2013106.","journal-title":"Nat Methods"},{"key":"1877_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1165\/rcmb.2020-0119OC","volume":"64","author":"S Kanagaki","year":"2021","unstructured":"Kanagaki S, Suezawa T, Moriguchi K, Nakao K, Toyomoto M, Yamamoto Y, Murakami K, Hagiwara M, Gotoh S. Hydroxypropyl cyclodextrin improves amiodarone-induced aberrant lipid homeostasis of alveolar cells. Am J Respir Cell Mol Biol. 2021;64:504\u201314.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1877_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-018-0686-x","volume":"563","author":"MW Shen","year":"2018","unstructured":"Shen MW, Arbab M, Hsu JY, Worstell D, Culbertson SJ, Krabbe O, Cassa CA, Liu DR, Gifford DK, Sherwood RI. Predictable and precise template-free CRISPR editing of pathogenic variants. Nature. 2018;563:646\u201351.","journal-title":"Nature"},{"key":"1877_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","volume":"4","author":"HL Li","year":"2015","unstructured":"Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep. 2015;4:143\u201354.","journal-title":"Stem Cell Rep"},{"key":"1877_CR24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/s12276-020-0466-1","volume":"52","author":"HK Jang","year":"2020","unstructured":"Jang HK, Song B, Hwang GH, Bae S. Current trends in gene recovery mediated by the CRISPR-Cas system. Exp Mol Med. 2020;52:1016\u201327.","journal-title":"Exp Mol Med"},{"key":"1877_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1076-8","volume":"568","author":"S Iyer","year":"2019","unstructured":"Iyer S, Suresh S, Guo D, Daman K, Chen JCJ, Liu P, Zieger M, Luk K, Roscoe BP, Mueller C, et al. Precise therapeutic gene correction by a simple nuclease-induced double-stranded break. Nature. 2019;568:561\u20135.","journal-title":"Nature"},{"key":"1877_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/ng1196-300","volume":"14","author":"J Oh","year":"1996","unstructured":"Oh J, Bailin T, Fukai K, Feng GH, Ho L, Mao JI, Frenk E, Tamura N, Spritz RA. Positional cloning of a gene for Hermansky\u2013Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet. 1996;14:300\u20136.","journal-title":"Nat Genet"},{"key":"1877_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ymgme.2014.11.006","volume":"114","author":"Y Ikawa","year":"2015","unstructured":"Ikawa Y, Hess R, Dorward H, Cullinane AR, Huizing M, Gochuico BR, Gahl WA, Candotti F. In vitro functional correction of Hermansky\u2013Pudlak Syndrome type-1 by lentiviral-mediated gene transfer. Mol Genet Metab. 2015;114:62\u20135.","journal-title":"Mol Genet Metab"},{"key":"1877_CR28","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1016\/j.celrep.2019.05.077","volume":"27","author":"A Strikoudis","year":"2019","unstructured":"Strikoudis A, Cie\u015blak A, Loffredo L, Chen YW, Patel N, Saqi A, Lederer DJ, Snoeck HW. Modeling of fibrotic lung disease using 3D organoids derived from human pluripotent stem cells. Cell Rep. 2019;27:3709-3723.e3705.","journal-title":"Cell Rep"},{"key":"1877_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1086\/301611","volume":"61","author":"S Hazelwood","year":"1997","unstructured":"Hazelwood S, Shotelersuk V, Wildenberg SC, Chen D, Iwata F, Kaiser-Kupfer MI, White JG, King RA, Gahl WA. Evidence for locus heterogeneity in Puerto Ricans with Hermansky\u2013Pudlak syndrome. Am J Hum Genet. 1997;61:1088\u201394.","journal-title":"Am J Hum Genet"},{"key":"1877_CR30","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI36183","volume":"119","author":"M Zeisberg","year":"2009","unstructured":"Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429\u201337.","journal-title":"J Clin Invest"},{"key":"1877_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.tips.2021.01.007","volume":"42","author":"RK Kortekaas","year":"2021","unstructured":"Kortekaas RK, Burgess JK, van Orsoy R, Lamb D, Webster M, Gosens R. Therapeutic targeting of IL-11 for chronic lung disease. Trends Pharmacol Sci. 2021;42:354\u201366.","journal-title":"Trends Pharmacol Sci"},{"key":"1877_CR32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ydbio.2008.02.035","volume":"317","author":"C Gontan","year":"2008","unstructured":"Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol. 2008;317:296\u2013309.","journal-title":"Dev Biol"},{"key":"1877_CR33","doi-asserted-by":"publisher","first-page":"E4456","DOI":"10.1073\/pnas.1311847110","volume":"110","author":"BE Rockich","year":"2013","unstructured":"Rockich BE, Hrycaj SM, Shih HP, Nagy MS, Ferguson MA, Kopp JL, Sander M, Wellik DM, Spence JR. Sox9 plays multiple roles in the lung epithelium during branching morphogenesis. Proc Natl Acad Sci U S A. 2013;110:E4456-4464.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1877_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.stem.2019.12.009","volume":"26","author":"K Hurley","year":"2020","unstructured":"Hurley K, Ding J, Villacorta-Martin C, Herriges MJ, Jacob A, Vedaie M, Alysandratos KD, Sun YL, Lin C, Werder RB, et al. Reconstructed single-cell fate trajectories define lineage plasticity windows during differentiation of human PSC-derived distal lung progenitors. Cell Stem Cell. 2020;26:593-608.e598.","journal-title":"Cell Stem Cell"},{"key":"1877_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1237","author":"B Ng","year":"2019","unstructured":"Ng B, Dong J, D\u2019Agostino G, Viswanathan S, Widjaja AA, Lim WW, Ko NSJ, Tan J, Chothani SP, Huang B, et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aaw1237.","journal-title":"Sci Transl Med"},{"key":"1877_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90558","volume":"1","author":"Y Xu","year":"2016","unstructured":"Xu Y, Mizuno T, Sridharan A, Du Y, Guo M, Tang J, Wikenheiser-Brokamp KA, Perl AT, Funari VA, Gokey JJ, et al. Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. JCI Insight. 2016;1: e90558.","journal-title":"JCI Insight"},{"key":"1877_CR37","doi-asserted-by":"publisher","first-page":"L887","DOI":"10.1152\/ajplung.00451.2020","volume":"319","author":"N Neumark","year":"2020","unstructured":"Neumark N, Cosme C Jr, Rose KA, Kaminski N. The idiopathic pulmonary fibrosis cell atlas. Am J Physiol Lung Cell Mol Physiol. 2020;319:L887-l893.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1877_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1983","volume":"6","author":"TS Adams","year":"2020","unstructured":"Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F, Chu SG, Raby BA, DeIuliis G, Januszyk M, et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv. 2020;6: eaba1983.","journal-title":"Sci Adv"},{"key":"1877_CR39","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1172\/JCI139519","volume":"130","author":"J Katzen","year":"2020","unstructured":"Katzen J, Beers MF. Contributions of alveolar epithelial cell quality control to pulmonary fibrosis. J Clin Invest. 2020;130:5088\u201399.","journal-title":"J Clin Invest"},{"key":"1877_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-6346-1_2","volume":"1473","author":"S Sakamuru","year":"2016","unstructured":"Sakamuru S, Attene-Ramos MS, Xia M. Mitochondrial membrane potential assay. Methods Mol Biol. 2016;1473:17\u201322.","journal-title":"Methods Mol Biol"},{"key":"1877_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101509","volume":"33","author":"M Bueno","year":"2020","unstructured":"Bueno M, Calyeca J, Rojas M, Mora AL. Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis. Redox Biol. 2020;33: 101509.","journal-title":"Redox Biol"},{"key":"1877_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12931-021-01640-z","volume":"22","author":"K Cuevas-Mora","year":"2021","unstructured":"Cuevas-Mora K, Roque W, Shaghaghi H, Gochuico BR, Rosas IO, Summer R, Romero F. Hermansky\u2013Pudlak syndrome-2 alters mitochondrial homeostasis in the alveolar epithelium of the lung. Respir Res. 2021;22:49.","journal-title":"Respir Res"},{"key":"1877_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1165\/rcmb.2016-0426PS","volume":"57","author":"MF Beers","year":"2017","unstructured":"Beers MF, Moodley Y. When is an alveolar type 2 cell an alveolar type 2 cell? A Conundrum for lung stem cell biology and regenerative medicine. Am J Respir Cell Mol Biol. 2017;57:18\u201327.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1877_CR44","unstructured":"Hans-Willem S, Ya-Wen C, Aabra A. Generation of three-dimensional lung bud organoid and its derived branching colonies. Protoc Exch. 2017."},{"key":"1877_CR45","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1159\/000488166","volume":"45","author":"M Zhao","year":"2018","unstructured":"Zhao M, Liu Y, Liu R, Qi J, Hou Y, Chang J, Ren L. Upregulation of IL-11, an IL-6 family cytokine, promotes tumor progression and correlates with poor prognosis in non-small cell lung cancer. Cell Physiol Biochem. 2018;45:2213\u201324.","journal-title":"Cell Physiol Biochem"},{"key":"1877_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.3901","volume":"21","author":"MT Grande","year":"2015","unstructured":"Grande MT, S\u00e1nchez-Laorden B, L\u00f3pez-Blau C, De Frutos CA, Boutet A, Ar\u00e9valo M, Rowe RG, Weiss SJ, L\u00f3pez-Novoa JM, Nieto MA. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 2015;21:989\u201397.","journal-title":"Nat Med"},{"key":"1877_CR47","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/labinvest.2015.114","volume":"95","author":"HR Jonsdottir","year":"2015","unstructured":"Jonsdottir HR, Arason AJ, Palsson R, Franzdottir SR, Gudbjartsson T, Isaksson HJ, Gudmundsson G, Gudjonsson T, Magnusson MK. Basal cells of the human airways acquire mesenchymal traits in idiopathic pulmonary fibrosis and in culture. Lab Invest. 2015;95:1418\u201328.","journal-title":"Lab Invest"},{"key":"1877_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00418-010-0724-8","volume":"134","author":"L Wang","year":"2010","unstructured":"Wang L, Lyerla T. Histochemical and cellular changes accompanying the appearance of lung fibrosis in an experimental mouse model for Hermansky\u2013Pudlak syndrome. Histochem Cell Biol. 2010;134:205\u201313.","journal-title":"Histochem Cell Biol"},{"key":"1877_CR49","doi-asserted-by":"publisher","first-page":"E1475","DOI":"10.1073\/pnas.1117988108","volume":"108","author":"JR Rock","year":"2011","unstructured":"Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108:E1475-1483.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1877_CR50","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1096\/fasebj.2020.34.s1.04611","volume":"34","author":"S Kook","year":"2020","unstructured":"Kook S, Meng S, Rasmussen ML, Trenary I, Young JD, Gama V, Guttentag SH. Impaired mitochondrial respiration in Hermansky\u2013Pudlak syndrome 1-defective alveolar type 2 cells is associated with enhanced mitochondrial fission. FASEB J. 2020;34:S1-1.","journal-title":"FASEB J"},{"key":"1877_CR51","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1172\/JCI99287","volume":"128","author":"SI Nureki","year":"2018","unstructured":"Nureki SI, Tomer Y, Venosa A, Katzen J, Russo SJ, Jamil S, Barrett M, Nguyen V, Kopp M, Mulugeta S, Beers MF. Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis. J Clin Invest. 2018;128:4008\u201324.","journal-title":"J Clin Invest"},{"key":"1877_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109636","volume":"36","author":"KD Alysandratos","year":"2021","unstructured":"Alysandratos KD, Russo SJ, Petcherski A, Taddeo EP, Ac\u00edn-P\u00e9rez R, Villacorta-Martin C, Jean JC, Mulugeta S, Rodriguez LR, Blum BC, et al. Patient-specific iPSCs carrying an SFTPC mutation reveal the intrinsic alveolar epithelial dysfunction at the inception of interstitial lung disease. Cell Rep. 2021;36: 109636.","journal-title":"Cell Rep"},{"key":"1877_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-physiol-012110-142225","volume":"73","author":"HA Chapman","year":"2011","unstructured":"Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol. 2011;73:413\u201335.","journal-title":"Annu Rev Physiol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-021-01877-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T13:10:19Z","timestamp":1636031419000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01877-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1186\/s12931-021-01877-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Teratoma formation assay was performed under approval by Animal Research Committee of Kyoto University. Using HFLFs was exemption from requiring ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.S., S.K., K.N. and K.M. received personal fees and research funding from Kyorin Pharmaceutical Co., Ltd, and are shareholders of it. M.H. and S.G. are founders and shareholders of HiLung Inc. M.H. received research funding from Kyorin Pharmaceutical. S.G. is listed as one of the inventors of Kyoto University\u2019s patents related to the method of generating alveolar organoids. The other authors declared no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}